Currently, treatment strategies involving CD82 as a therapeutic target to hinder breast cancer spread has not been fully exploited, even though potential drugs such as the TKIs, lapatinib, neratinib, and tucatinib have been approved for MBC treatment, while imatinib and etoposide have been investigated in clinical trials for MBC. The gene discussed is CD82; the disease is breast carcinoma.